Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients

已完结 10 由火星上的烘焙坊发布于 2025/12/28 20:46:07

DOI:10.1016/j.cell.2024.12.010
作者：Liping Zhong, Lu Gan, Bing Wang, Tao Wu, Fei Yao, Wenlin Gong, Hongmei Peng, Zhiming Deng, Guoyou Xiao, Xiyu Liu, Jintong Na, Desong Xia, Xianjun Yu, Zhikun Zhang, Bangde Xiang, Yu Huo, Dan Yan, Zhixi
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Recently, oncolytic virus (OV) therapy has shown great promise in treating malignancies. However, intravenous safety and inherent lack of immunity are two significant limitations in clinical

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:知网1-MCP处理对西梅果实贮藏品质及酚类物质代谢的影响